APA

Chiarion-Sileni V., Del Bianco P., Romanini A., Guida M., Paccagnella A., Dalla Palma M., Naglieri E., Ridolfi R., Silvestri B., Michiara M. & De Salvo G. L. (20060605). Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. : BMC cancer.

Chicago

Chiarion-Sileni Vanna, Del Bianco Paola, Romanini Antonella, Guida Michele, Paccagnella Adriano, Dalla Palma Maurizio, Naglieri Emanuele, Ridolfi Ruggero, Silvestri Barbara, Michiara Maria and De Salvo Gian Luca. 20060605. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. : BMC cancer.

Harvard

Chiarion-Sileni V., Del Bianco P., Romanini A., Guida M., Paccagnella A., Dalla Palma M., Naglieri E., Ridolfi R., Silvestri B., Michiara M. and De Salvo G. L. (20060605). Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. : BMC cancer.

MLA

Chiarion-Sileni Vanna, Del Bianco Paola, Romanini Antonella, Guida Michele, Paccagnella Adriano, Dalla Palma Maurizio, Naglieri Emanuele, Ridolfi Ruggero, Silvestri Barbara, Michiara Maria and De Salvo Gian Luca. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. : BMC cancer. 20060605.